3(或 5)-氨基-2-羟基苯甲酸（CAS 51481-17-5）：分子式 C7H7NO3、分子量 153.14。
| CAS号 | 51481-17-5 |
|---|---|
| 分子式 | C7H7NO3 |
| 分子量 | 153.14 |
| 熔点 | 260-280 °C |
| LogP | 1.2 |
| 应用领域 | Uses: Used to make dyes and light-sensitive paper、Also used as a gastrointestinal anti-inflammatory drug、[Merck Index] A metabolite of the drug sulfasalazine、[REPROTOX]、In manufacture of light-sensitive paper、azo and sulfur dyes、Treatment of ulcerative colitis (England)、It is used orally、in a delay-release formulation、as a retention enema、and as a suppository.、THERAP CAT: Anti-inflammatory (gastrointestinal)、Synthetic Polymer MALDI Matrix Compounds、Use (kg) in Switzerland (2009): >5000、Use (kg、approx.) in Germany (2009): >75000、exact) in Germany (2009): 96794、Use (kg) in USA (2002): 136000、Consumption (g per capita) in Switzerland (2009): 0.64、Consumption (g per capita、approx.) in Germany (2009): 0.92、exact) in Germany (2009): 1.2、Consumption (g per capita) in the USA (2002): 0.48、Excretion rate: 0.1、Calculated removal (%): 92.1、Use Classification: Pharmaceuticals、Methods of Manufacturing: Preparation by reduction of m-nitrobenzoic acid with Zn dust and HCl、Formulations、Preparations: ... The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon、making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. ...、Oral: Capsules、extended-release: 250 mg Pentasa、(Shire)、500 mg Pentasa、(Shire). Tablets、delayed-release: 400 mg Asacol、(Procter & Gamble). Rectal: Suppositories: 500 mg Canasa、(Axcan Scandipharm)、1 g Canasa、(Axcan Scandipharm). Suspension: 4 g、60 mL Mesalamine Suspension Enema、(Clay-Park)、Mesalamine Suspension Enema、(Teva)、Rowasa Suspension Enema (with potassium metabisulfite)、(Solvay).、Oral: Tablet Delayed Release: 1.2 g Lialda (Shire).、Consumption Patterns: (2000、England) 40、421.72 kg、yr、General Manufacturing Information: Benzoic acid、5-amino-2-hydroxy-: ACTIVE、One of the top 25 English prescription pharmaceuticals in 2000. |
登记用途：Uses: Used to make dyes and light-sensitive paper、Also used as a gastrointestinal anti-inflammatory drug、[Merck Index] A metabolite of the drug sulfasalazine、[REPROTOX]、In manufacture of light-sensitive paper、azo and sulfur dyes、Treatment of ulcerative colitis (England)、It is used orally、in a delay-release formulation、as a retention enema、and as a suppository.、THERAP CAT: Anti-inflammatory (gastrointestinal)、Synthetic Polymer MALDI Matrix Compounds、Use (kg) in Switzerland (2009): >5000、Use (kg、approx.) in Germany (2009): >75000、exact) in Germany (2009): 96794、Use (kg) in USA (2002): 136000、Consumption (g per capita) in Switzerland (2009): 0.64、Consumption (g per capita、approx.) in Germany (2009): 0.92、exact) in Germany (2009): 1.2、Consumption (g per capita) in the USA (2002): 0.48、Excretion rate: 0.1、Calculated removal (%): 92.1、Use Classification: Pharmaceuticals、Methods of Manufacturing: Preparation by reduction of m-nitrobenzoic acid with Zn dust and HCl、Formulations、Preparations: ... The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon、making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. ...、Oral: Capsules、extended-release: 250 mg Pentasa、(Shire)、500 mg Pentasa、(Shire). Tablets、delayed-release: 400 mg Asacol、(Procter & Gamble). Rectal: Suppositories: 500 mg Canasa、(Axcan Scandipharm)、1 g Canasa、(Axcan Scandipharm). Suspension: 4 g、60 mL Mesalamine Suspension Enema、(Clay-Park)、Mesalamine Suspension Enema、(Teva)、Rowasa Suspension Enema (with potassium metabisulfite)、(Solvay).、Oral: Tablet Delayed Release: 1.2 g Lialda (Shire).、Consumption Patterns: (2000、England) 40、421.72 kg、yr、General Manufacturing Information: Benzoic acid、5-amino-2-hydroxy-: ACTIVE、One of the top 25 English prescription pharmaceuticals in 2000.。
3(或 5)-氨基-2-羟基苯甲酸 是一种化工化合物，登记 CAS 号为 51481-17-5，分子式 C7H7NO3（分子量 153.14）。
登记 CAS 号：51481-17-5
其分子式 C7H7NO3 由 7 个碳、7 个氢、1 个氮、3 个氧 组成。
别名/同义词：3(或 5)-氨基-2-羟基苯甲酸 · 3(or 5)-aminosalicylic acid
3(或 5)-氨基-2-羟基苯甲酸 的 CAS 登记号为 51481-17-5。
分子式 C7H7NO3，分子量 153.14。
别名/同义词：3(或 5)-氨基-2-羟基苯甲酸、3(or 5)-aminosalicylic acid。
登记用途：Uses: Used to make dyes and light-sensitive paper、Also used as a gastrointestinal anti-inflammatory drug、[Merck Index] A metabolite of the drug sulfasalazine、[REPROTOX]、In manufacture of light-sensitive paper、azo and sulfur dyes、Treatment of ulcerative colitis (England)、It is used orally、in a delay-release formulation、as a retention enema、and as a suppository.、THERAP CAT: Anti-inflammatory (gastrointestinal)、Synthetic Polymer MALDI Matrix Compounds、Use (kg) in Switzerland (2009): >5000、Use (kg、approx.) in Germany (2009): >75000、exact) in Germany (2009): 96794、Use (kg) in USA (2002): 136000、Consumption (g per capita) in Switzerland (2009): 0.64、Consumption (g per capita、approx.) in Germany (2009): 0.92、exact) in Germany (2009): 1.2、Consumption (g per capita) in the USA (2002): 0.48、Excretion rate: 0.1、Calculated removal (%): 92.1、Use Classification: Pharmaceuticals、Methods of Manufacturing: Preparation by reduction of m-nitrobenzoic acid with Zn dust and HCl、Formulations、Preparations: ... The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon、making it most useful in the treatment of ulcerative colitis. The MMX coating matrix and coating system begin dissolution in the final portion of the ileum. ...、Oral: Capsules、extended-release: 250 mg Pentasa、(Shire)、500 mg Pentasa、(Shire). Tablets、delayed-release: 400 mg Asacol、(Procter & Gamble). Rectal: Suppositories: 500 mg Canasa、(Axcan Scandipharm)、1 g Canasa、(Axcan Scandipharm). Suspension: 4 g、60 mL Mesalamine Suspension Enema、(Clay-Park)、Mesalamine Suspension Enema、(Teva)、Rowasa Suspension Enema (with potassium metabisulfite)、(Solvay).、Oral: Tablet Delayed Release: 1.2 g Lialda (Shire).、Consumption Patterns: (2000、England) 40、421.72 kg、yr、General Manufacturing Information: Benzoic acid、5-amino-2-hydroxy-: ACTIVE、One of the top 25 English prescription pharmaceuticals in 2000.。
3(或 5)-氨基-2-羟基苯甲酸（CAS 51481-17-5）的独立参考数据，整理自公开化学数据库。
| CAS 号 | 51481-17-5 |
|---|---|
| PubChem CID | 4075 |
| 分子式 | C7H7NO3 |
| IUPAC 名称 | 5-amino-2-hydroxybenzoic acid |
| UNII（FDA） | 4Q81I59GXC |
| Molecular Weight | 153.14 |
|---|---|
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 153.042593085 |
| Monoisotopic Mass | 153.042593085 |
| Topological Polar Surface Area | 83.6 |
| Heavy Atom Count | 11 |
| Melting Point | 260-280 °C |
|---|---|
| Melting Point | 283 °C |
| Solubility | 0.84 |
| Solubility | 1.22e+01 g/L |
| Vapor Pressure | 0.00000006 [mmHg] |
| LogP | 1.2 |
| LogP | 0.48 |
5-Aminosalicylic acid; mesalamine; 89-57-6; Mesalazine; 5-Amino-2-hydroxybenzoic acid; 5-ASA; Fisalamine; Lialda; m-Aminosalicylic acid; Benzoic acid, 5-amino-2-hydroxy-; Mesalazina; sfRowasa; Apriso; p-Aminosalicylsaeure; Asacolitin; Mesalazinum
| GHS 通报统计 | 0.5% (1 / 195) |
|---|
| GHS 通报统计 | 0.5% (1 / 195) |
|---|---|
| 已通报的危害声明 | H315 (81.5%), H317 (44.1%), H319 (81.5%), H335 (81%), H412 (17.9%) |
3(或 5)-氨基-2-羟基苯甲酸 · CAS 51481-17-5 · C7H7NO3. UNII 4Q81I59GXC. Melting Point: 260-280 °C; Melting Point: 283 °C; Solubility: 0.84.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: 3(or 5)-aminosalicylic acid